Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 103
Immunization Safety Review: Hepatitis B Vaccine and Demyelinating Neurological Disorders Appendix C Chronology of Important Events Regarding Vaccine Safety Year Vaccine Licensure Legislation and/or Policy Statements IOM Reports on Vaccine Safety 1955 Inactivated poliomyelitis vaccine (IPV) available 1963 Oral poliomyelitis vaccine (OPV) available, replaces IPV Measles vaccine available 1967 Mumps vaccine available 1969 Rubella vaccine available 1971 Measles-Mumps-Rubella (MMR) vaccine available 1977 Mumps vaccination recommended Evaluation of Poliomyelitis Vaccines 1979 Current formulation of rubella vaccine available, replaces earlier versions 1982 Plasma-derived hepatitis B vaccine available
OCR for page 104
Immunization Safety Review: Hepatitis B Vaccine and Demyelinating Neurological Disorders Year Vaccine Licensure Legislation and/or Policy Statements IOM Reports on Vaccine Safety 1985 Hib vaccine licensed for children>15 months 1986 Congress passes Public Law 99–660, the National Childhood Vaccine Injury Act (introduced in 1984) calls for: • est of NVPO • est. of NVAC • est. of VICP • est. of ACCV IOM review of 1) pertussis and rubella, 2) routine child vaccines 1988 Evaluation of Poliomyelitis Vaccine Policy Options 1990 2 Hib conjugate vaccines licensed for use beginning at 2 months 1991 Acellular pertussis component licensed for the 4th and 5th doses of the 5-part DTP series in ACEL-IMUNE Hepatitis B recommended by ACIP for addition to childhood immunization schedule Adverse Effects of Pertussis and Rubella Vaccines ACIP recommends Hib be added to childhood immunization schedule 1992 Acellular pertussis component licensed for the 4th and 5th doses of the 5-part DTP series in Tripedia Hepatitis B vaccine: Added universal vaccination for all infants, high-risk adolescents (e.g., IV drug users, persons with multiple sex partners) 1993 Combined DTP and Hib vaccine (Tetramune) licensed 1994 Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality DPT and Chronic Nervous System Dysfunction: A New Analysis 1995 Varicella virus vaccine available (Varivax)
OCR for page 105
Immunization Safety Review: Hepatitis B Vaccine and Demyelinating Neurological Disorders Year Vaccine Licensure Legislation and/or Policy Statements IOM Reports on Vaccine Safety 1996 DTaP vaccine licensed for first three doses given in infancy (Tripedia and ACEL-IMUNE were previously licensed for only the 4th and 5th doses). ACIP recommends using IPV for the first 2 polio vaccinations, followed by OPV for remaining doses. Intended to be a transitional schedule for 3–5 years until an all-IPV series is available Options for Poliomyelitis Vaccinations in the United States: Workshop Summary ACIP recommends children 12months–12 years receive Varicella vaccine 1997 Additional DTaP vaccine (Infanrix) licensed for first 4 doses of 5-part series ACIP recommends DTaP in place of DTP Vaccine Safety Forum: Summary of Two Workshops Risk Communication and Vaccination: Workshop Summary 1998 Additional DTaP vaccine (Certiva) licensed for first 4 doses of 5-part series ACIP updates MMR recommendation, encouraging use of the combined MMR vaccine 1999 ACIP updates varicella vaccine recommendation, requiring immunity for child care and school entry ACIP recommends an all-IPV schedule begin January 2000 to prevent cases of vaccine-associated paralytic polio AAP and PHS recommend removal of thimerosal from vaccines Also recommended postponement of hepatitis B vaccine from birth to 2–6 months for infants of hepatitis B surface antigen-negative mothers Additional supply of thimerosal-free hepatitis B vaccine made available MMWR notifies readers of the availability of a thimerosal-free hepatitis B vaccine, enabling the resumption of the birth dose 2000 Pneumococcal vaccine for infants and young ACIP recommends pneumococcal vaccination for all chil
OCR for page 106
Immunization Safety Review: Hepatitis B Vaccine and Demyelinating Neurological Disorders Year Vaccine Licensure Legislation and/or Policy Statements IOM Reports on Vaccine Safety children licensed (Prevnar) dren 2–23 months, and at-risk children 24–59 months (e.g., immunocompromised) 2001 October: ACIP drafts statement expressing a preference for use of thimerosal-free DtaP, Hib, and Hep B vaccines by March 2002 Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism Immunization Safety Review: Thimerosal-Containing Vaccines and Neurodevelopmental Disorders 2002 Immunization Safety Review: Multiple Immunizations and Immune Dysfunction
Representative terms from entire chapter: